Specialists in modelling non-communicable diseases

Tackling population health challenges means asking big questions, such as:

What impact would a tax on sugary drinks have on reducing obesity over the next 20 years?
How can you look 10 to 20 years ahead to understand the impact of a new drug on its users and your revenue stream?
How should you plan for changing levels of chronic disease caused by climate change?
What impact will different levels of air quality have on healthcare costs between now and 2050?
How can you boost a nation’s health with targeted help at different life stages?

And how do you even know which are the right questions to ask?

That’s where we can help.

Helping you make the best decisions

Our simulation and analysis expertise turns tomorrow’s population health questions and challenges into today’s focussed, specific, actionable decisions.

We can help you understand and explore those questions and challenges far into the future. Our scenario modelling will show you how different kinds of health interventions, drug innovations and policy changes can impact them.

And that will help you choose the best way forward.

Why Us?

Deep expertise in modelling non-communicable diseases, combined with entrepreneurial vision.

Why Us?

How do we do it?

We’ve created a specific process to help you find, ask and answer the right questions.

Method

What have we done?

We’ve answered many different kinds of questions for many different organisations in over 70 countries.

Track Record

Why choose us?

We have an experienced and multi-disciplinary team of software engineers, population health and policy research experts, and mathematicians.

Team

HealthLumen Blog

The future burden of chronic kidney disease (CKD): how we have climbed “INSIDE CKD” with AstraZeneca using microsimulation-based computer modelling to help improve health outcomes

HealthLumen, in conjunction with AstraZeneca, have recently published a body of research from the “INSIDE CKD” programme, part of a major strategic initiative at AstraZeneca which is dedicated to changing the future for CKD patients. Our role is to support evidence-based policy making in CKD, which we do by harnessing the predictive power of microsimulation, […]

Read

How leaving the car at home might improve health

An analysis of the effect of lockdown on air pollution-related health in two London boroughs People around the world have spent parts of 2020 in lockdown. The Covid-19 pandemic has caused thousands of tragic deaths and damaged many people’s health directly and indirectly, but new research has shed light on a much-needed positive health development […]

Read

Intern Series (4)

We’re pleased to share the latest in our series of posts from our interns. Daniel Ohrenstein has just completed an extended 5-month stay with us working on some exciting new techniques for multiple risk factor modelling. Daniel Ohrenstein I recently completed an MSc in Machine Learning and Data Science at UCL, having graduated with a […]

Read

Why we must work toward a recognised international standard in evaluation of upstream interventions

New blog published this week by Evidence & Policy co-authored by our COO and Co-Founder Laura Webber. The blog builds off research by Laura and collaborators at Lancaster University and the University of York on the health impacts universal basic income (UBI) could have. The role of UBI has come to the fore during the […]

Read